Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study

References

• Tanaka T, Narazaki M, Kishimoto T. Interleukin (Il-6) immunotherapy. Cold Spring Harb Perspect Biol. 2018;10(8):a028456. doi: 10.1101/cshperspect.a028456
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report for RoActemra [Internet]. 2009 [cited 2023 Jul 20]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/roactemra-epar-public-assessment-report_en.pdf
   Google Scholar
• US Food and Drug Administration. Highlights of prescribing information: ACTEMRA (tocilizumab) [Internet]. 2010 [cited 2023 Jul 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125276lbl.pdf
   Google Scholar
• European Medicines Agency. RoActemra summary of product characteristics [Internet]. 2023 [cited 2023 Jul 14]. Available from: https://www.ema.europa.eu/en/documents/product-information/roactemra-epar-product-information_en.pdf
   Google Scholar
• US Food and Drug Administration. Highlights of prescribing information: ACTEMRA (tocilizumab) [Internet]. 2022 [cited 2023 Oct 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125472s049lbl.pdf
   Google Scholar
• European Medicines Agency. Tyenne summary of product characteristics [Internet]. 2023 [cited 2023 Oct 17]. Available from: https://www.ema.europa.eu/en/documents/product-information/tyenne-epar-product-information_en.pdf
   Google Scholar
• US Food and Drug Administration. Drugs@FDA: FDA-approved drugs [Internet]. 2023 [cited 2023 Oct 17]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761354
   Google Scholar
• Mehr S. Tocilizumab biosimilars approaching: developments on three fronts [Internet]. 2022 [cited 2023 Jul 14]. Available from: https://biosimilarsrr.com/2022/08/18/tocilizumab-biosimilars-approaching-developments-on-three-fronts/
   Google Scholar
• Yu KS, Kim B, Shin D, et al. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study. Expert Opin Investig Drugs. 2023;32(5):429–439. doi: 10.1080/13543784.2023.2212155
   PubMed Web of Science ®Google Scholar
• Hsiao B, Fraenkel L. Patient preferences for rheumatoid arthritis treatment. Curr Opin Rheumatol. 2019;31(3):256–263. doi: 10.1097/BOR.0000000000000591
   PubMed Web of Science ®Google Scholar
• Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28(10):1619–1629. doi: 10.1016/j.clinthera.2006.10.006
   PubMed Web of Science ®Google Scholar
• Rho YH, Rychlewska-Hanczewska A, Sliwowska B, et al. Usability of prefilled syringe and autoinjector for sb4 (an etanercept biosimilar) in patients with rheumatoid arthritis. Adv Ther. 2019;36(9):2287–2295. doi: 10.1007/s12325-019-01027-z
   PubMed Web of Science ®Google Scholar
• Roszkiewicz J, Swacha Z, Smolewska E. Prefilled pen versus prefilled syringe: a pilot study evaluating two different methods of methotrexate subcutaneous injection in patients with JIA. Pediatr Rheumatol Online J. 2020;18(1):64. doi: 10.1186/s12969-020-00455-4
   PubMed Web of Science ®Google Scholar
• Saraux A, Hudry C, Zinovieva E, et al. Use of auto-injector for methotrexate subcutaneous self-injections: high satisfaction level and good compliance in self-i study, a randomized, open-label, parallel group study. Rheumatol Ther. 2019;6(1):47–60. doi: 10.1007/s40744-018-0134-2
   PubMed Web of Science ®Google Scholar
• Kivitz A, Baret-Cormel L, van Hoogstraten H, et al. Usability and patient preference phase 3 study of the sarilumab pen in patients with active moderate-to-severe rheumatoid arthritis. Rheumatol Ther. 2018;5(1):231–242. doi: 10.1007/s40744-017-0090-2
   PubMed Web of Science ®Google Scholar
• Schwarzenbach F, Dao Trong M, Grange L, et al. Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis. Patient Prefer Adherence. 2014;8:199–209. doi: 10.2147/PPA.S50583
   PubMed Web of Science ®Google Scholar
• Xiao X, Li W, Clawson C, et al. Evaluation of performance, acceptance, and compliance of an auto-injector in healthy and rheumatoid arthritic subjects measured by a motion capture system. Patient Prefer Adherence. 2018;12:515–526. doi: 10.2147/PPA.S160394
   PubMed Web of Science ®Google Scholar
• Duruoz MT, Poiraudeau S, Fermanian J, et al. Development and validation of a rheumatoid hand functional disability scale that assesses functional handicap. J Rheumatol. 1996;23:1167–1172.
   PubMed Web of Science ®Google Scholar
• Fettner S, Mela C, Wildenhahn F, et al. Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector. Expert Opin Drug Deliv. 2019;16(5):551–561. doi: 10.1080/17425247.2019.1604678.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product [Internet]. 2015 [cited 2023 Jul 17]. Available from: https://www.fda.gov/media/82647/download
   Google Scholar
• ClinicalTrials.gov. Compare the auto-injector and pre-filled syringe of CT-P47 in healthy subjects [Internet]. 2023 [cited 2023 Jul 18]. Available from: https://www.clinicaltrials.gov/study/NCT05617183?cond=NCT05617183&rank=1
   Google Scholar
• Sampson HA, Munoz-Furlong A, Campbell RL. et al. Second symposium on the definition and management of anaphylaxis: summary report – second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med. 2006;47:373–380. doi: 10.1016/j.annemergmed.2006.01.018
   PubMed Web of Science ®Google Scholar
• Tomaszewska-Kiecana M, Dryja A, Ullmann M, et al. Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults. Expert Rev Clin Immunol. 2023;19(4):447–455. doi: 10.1080/1744666X.2023.2174970
   PubMed Web of Science ®Google Scholar
• Morcos PN, Zhang X, McIntyre C, et al. Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20. Int J Clin Pharmacol Ther. 2013;51(7):537–548. doi: 10.5414/CP201847
   PubMed Web of Science ®Google Scholar
• Zhang X, Georgy A, Rowell L. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. Int J Clin Pharmacol Ther. 2013;51(6):443–455. doi: 10.5414/CP201819
   PubMed Web of Science ®Google Scholar
• Bush J, Kawakami K, Muniz R. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects. BMC Pharmacol Toxicol. 2019;20(1):87. doi: 10.1186/s40360-019-0376-9
   PubMed Web of Science ®Google Scholar
• Ramael S, Van Hoorick B, Tiessen R, et al. Similar pharmacokinetics of the adalimumab (Humira® biosimilar BI 695501 whether administered via subcutaneous autoinjector or prefilled syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): phase 1, randomized, open-label, parallel-group trials. Rheumatol Ther. 2018;5:403–421. doi: 10.1007/s40744-018-0119-1
   PubMed Web of Science ®Google Scholar
• Cherniakov I, Cohen-Barak O, Tiver R, et al. A pharmacokinetic bioequivalence study of fremanezumab administered subcutaneously using an autoinjector and a prefilled syringe. Clin Pharmacol Drug Dev. 2021;10(9):1018–1027. doi: 10.1002/cpdd.902
   PubMed Web of Science ®Google Scholar
• Shin D, Lee Y, Jeong D, et al. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects. Drug Des Devel Ther. 2018;12:3799–3805. doi: 10.2147/DDDT.S169082
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study to compare efficacy and safety of CT-P47 and RoActemra in patients with rheumatoid arthritis [Internet]. 2022 [cited 2023 Jul 17]. Available from: https://www.clinicaltrials.gov/study/NCT05489224?cond=NCT05489224&rank=1
   Google Scholar
• US Food and Drug Administration. Guidance for industry rheumatoid arthritis: developing drug products for treatment [Internet]. 2013 [cited 2023 Jul 28]. Available from: https://www.fda.gov/media/86066/download
   Google Scholar
• ClinicalTrials.gov. A study to evaluate usability of subcutaneous auto-injector of CT-P47 in patients with active rheumatoid arthritis [Internet]. 2023 [cited 2023 Jul 17]. Available from: https://www.clinicaltrials.gov/study/NCT05725434?intr=CT-P47&rank=2
   Google Scholar